|
|
|
|
|
Propranolol
drug data and news
Propranolol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Propranolol | ||
| Brand Names/Synonyms | Angilol; Apsolol; Avlocardyl; Bedranol; Beprane; Berkolol; Beta-Neg; Beta-Propranolol; Beta-Tablinen; Beta-Timelets; Betachron; Betalong; Cardinol; Caridolol; Corpendol; Deralin; Dl-Propranolol Hydrochloride; Dociton; Duranol; Efektolol; Elbrol; Etalong; Euprovasin; Frekven; Inderal; Inderal La; Inderide; Indobloc; Innopran Xl; Intermigran; Kemi S; Obsidan; Oposim; Prano-Puren; Propanalol; Propanix; Propanolol; Prophylux; Propranalol; Propranolol; Propranolol Hcl; Propranolol Hcl Intensol; Propranolol Hydrochloride; Propranur; Proprasylyt; Pylapron; R,S-Propranolol Hydrochloride; Rapynogen; Reducor; Reducor Line; Sagittol; Servanolol; Sloprolol; Sumial; Tesnol | ||
| Indication | For the prophylaxis of migraine | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Propranolol, the prototype of the beta-adrenergic receptor antagonists, is a competitive, nonselective beta-blocker similar to nadolol without intrinsic sympathomimetic activity. Propanolol is a racemic compound; the l-isomer is responsible for adrenergic blocking activity. | ||
| Mechanism Of Action | Like atenolol and metoprolol, propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles. | ||
| Propranolol News (When available) |
Talk out the pain or just pop a pill May 11, 2006 New evidence shows how hormones wire the minds of men, women May 12, 2006 Blood Pressure Med Prevents Aortic Aneurysm in Mice with Marfan May 1, 2006 A fix to forget it Apr 24, 2006 Men and women wired to feel emotions differently, study shows Apr 21, 2006 Losartan prevents progression of Marfan syndrome in mice Apr 28, 2006 Ask the Clinician: Answers to Readers' Questions Apr 24, 2006 | ||
| Dosage Forms | Tablets, I.V. | ||
| Drug_Category | Vasodilator Agents; Anti-anxiety Agents; Antihypertensive Agents; Antiarrhythmic Agents; Adrenergic Agents; ATC:C07AA05 | ||
| Absorption | Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals | ||
| Interactions |
Interactions for Propranolol: Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if Propranolol HCl is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension. Caution should be exercised when patients receiving a beta blocker are administered a calcium-channel blocking drug, especially intravenous verapamil, for both agents may depress myocardial contractility or atrioventricular conduction. On rare occasions, the concomitant intravenous use of a beta blocker and verapamil has resulted in serious adverse reactions, especially in patients with severe cardiomyopathy, congestive heart failure, or recent myocardial infarction. Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported. Hypotension and cardiac arrest have been reported with the concomitant use of propranolol and haloperidol. Aluminum hydroxide gel: Greatly reduces intestinal absorption of propranolol. Ethanol: Slows the rate of absorption of propranolol. Phenytoin, phenobarbitone: and rifampin accelerate propranolol clearance. Chlorpromazine: When used concomitantly with propranolol, results in increased plasma levels of both drugs. Antipyrine: and lidocaine have reduced clearance when used concomitantly with propranolol. Thyroxine: May result in a lower than expected T3 concentration when used concomitantly with propranolol. Cimetidine Decreases the hepatic metabolism of propranolol, delaying elimination and incre:asing blood levels. Theophylline: Clearance is reduced when used concomitantly with propranolol. | ||
| Toxicity | Bradycardia, cardiac failure, hypotension, brochospasm; LD50=565mg/kg(orally in mice) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-(1-methylethylamino)-3-naphthalen-1-yloxy-propan-2-ol | ||
| Chemical Formula | C16H21NO2 | ||
| Molecular Weight | 259.343 g/mol | ||
| Smiles String | CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O | ||
| Melting Point | 163-164°C | ||
| Water Solubility | 0.070 mg/mL (HCl salt) | ||
| State | white, crystalline solid | ||
| LogP/Hphobicity | 3.585 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 4 hours | ||
| Protein Binding [%] | more than 90% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Propranolol.html http://www.rxlist.com/cgi/generic/propran.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00194 | ||
| CAS Registry Number | 525-66-6 | ||
| KEGG Compound ID | C07407 | ||
| PubChem ID | SID:153977 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 663719 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |